Anemia, Iron Deficiency Clinical Trial
— RtPOfficial title:
The Impact of Faba Bean Rich Bread on Iron Status, Postprandial Lipaemia and Satiety in Adults With Low Iron Stores
High levels of animal proteins (meat) in the diet are linked with a greater risk of developing heart disease and other long-term health conditions. Recently there has been a shift to plant-based diets including plant proteins such as pulses, defined as beans, peas, chickpeas and lentils. Pulses are a nutritious and sustainable form of plant protein which are rich in fibre and iron. Despite this, the UK population does not consume the recommended daily amount of pulses (80g/day equivalent to a large handful). In contrast, bread is commonly consumed but very little is known about how bread enriched with pulses influences the amount of iron that is digested and absorbed by the body as well as risk factors for developing heart disease and type 2 diabetes. The main purpose of this randomised controlled cross-over study is to determine how consuming bread enriched with pulses (in the form of faba bean flour at approximately 40% enrichment) compared with conventional white bread (100% wheat flour) influences the amount of iron absorbed in healthy males and females aged 18-50 years with low iron stores. Secondary aims are determining the effects on blood fats and sugar (glucose) and on feelings of fullness (also known as satiety) after eating the bread enriched in pulses and conventional white bread. Participants will be required: - To attend for seven study visits over a period of 60 days. - Consume a breakfast meal containing either the faba bean-enriched bread or conventional bread over two study periods, each consisting of one 7 hour study visit and two consecutive visits of 2 hours in duration. After 28 days, participants will return for the second study period as above, with a final study visit conducted 28 days later. - Give blood samples during 2 x 7 hour study visits - Complete visual analogue scales to rate appetite after consuming the faba bean-enriched and conventional white bread. - Record dietary intake prior to and during the study period.
Status | Not yet recruiting |
Enrollment | 16 |
Est. completion date | September 2025 |
Est. primary completion date | June 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Non-anaemic, males and pre-menopausal females (must have regular periods) - Aged 18-50 years old - BMI between 19 - 30 kg/m2 - Low iron stores (serum ferritin between 13-40 µg/L for females and 30-90 µg/L for males) Exclusion Criteria: - Food allergies or intolerances to faba beans (favism) or gluten - Diagnosed with anaemia (haemoglobin <115 g/L for females or <130 g/L for males) or haemochromatosis - C-reactive protein (>3mg/L) - Smokers - A history of alcohol abuse (> 14 units/ week) - CVD or medical history of MI or stroke in the past 12 months - Diabetes (fasting glucose >7.0 mmol/L) - Kidney, liver, pancreas or intestinal disease, gastrointestinal disorder or use of drugs likely to alter gastrointestinal function - Pregnancy, planning a pregnancy in the next six months or breastfeeding - Peri- and post-menopausal women or women with irregular periods - Planning on a weight-reducing regimen (lost >3kg in last 6 months) - Parallel participation in another intervention study - Hypertension (blood pressure > 140/90 mmHg), cancer, taking medication for hyperlipidaemia (statins), or inflammation - Taking vitamin or mineral supplements - Donated blood in the last 3 months - Any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention and metabolic study (such as a pacemaker) |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, University of Reading | Reading | Berkshire |
Lead Sponsor | Collaborator |
---|---|
University of Reading | King's College London, University of Leeds |
United Kingdom,
Lovegrove JA, O'Sullivan DM, Tosi P, Millan E, Todman LC, Bishop J, Chatzifragkou A, Clegg ME, Hammond J, Jackson KG, Jones PJ, Lignou S, Macready AL, McMeel Y, Parker J, Rodriguez-Garcia J, Sharp P, Shaw LJ, Smith LG, Tebbit M. 'Raising the Pulse': The environmental, nutritional and health benefits of pulse-enhanced foods. Nutr Bull. 2023 Mar;48(1):134-143. doi: 10.1111/nbu.12601. Epub 2023 Jan 17. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in the enrichment of whole blood haemoglobin with iron-57 stable isotope 30 days after consuming the faba bean-enriched bread and conventional bread. | The measurement of iron-57 in whole blood is a validated method for determining the absorption of iron from the bread given in the test meals (also known as bioavailability) | Day 0 (baseline), day 30 and day 60 | |
Secondary | Fasting concentrations of iron status markers | Serum ferritin (a measure of the level of iron stored by the body) and soluble transferrin receptor (a measure of functional iron status) will be measured by immunoassay. | Day 0 (baseline), day 30 and day 60 | |
Secondary | Fasting concentration of C-reactive protein (a marker of inflammation) | Inflammation, which is characterised by the acute-phase response to infection, can directly affect the concentrations of most iron status markers. C-reactive protein will be measured in the fasting blood sample collected at each study visit to aid the interpretation of the data for the iron status markers. | Day 0 (baseline), day 30 and day 60 | |
Secondary | Fasting levels of the full blood count parameters | The level of white blood cells, red blood cells, platelets, haematocrit and haemoglobin in the whole blood sample will be measured using a haematology analyser. | Day 0 (baseline), day 30 and day 60 | |
Secondary | Fasting concentration of total cholesterol, high-density lipoprotein-cholesterol, triacylglycerol and non-esterified fatty acids. | Serum lipids will be measured directly using a clinical chemistry analyser. | Day 0 (baseline), day 30 and day 60 | |
Secondary | Fasting low-density lipoprotein-cholesterol concentration | The low-density lipoprotein-cholesterol concentration will be calculated from the total cholesterol, high-density lipoprotein-cholesterol and triacylglycerol concentrations using the Friedewald formula. | Day 0 (baseline), day 30 and day 60 | |
Secondary | Postprandial concentrations of lipids after consuming the faba bean-enriched bread and control bread. | Serum triacylglycerol and non-esterified fatty acids will be measured in the postprandial blood samples collected for 360 minutes after each acute test meal. | Acute study on Days 0 and 30, blood taken prior to eating the test meal (0 minutes) and then at 15, 30, 45, 60, 90, 120, 180, 240, 300 and 360 minutes post meal ingestion. | |
Secondary | Fasting glucose concentration | Serum glucose will be measured using a clinical chemistry analyser. | Day 0 (baseline), day 30 and day 60 | |
Secondary | Fasting insulin concentration | Serum insulin will be measured using an enzyme-lined immunosorbent assay. | Day 0 (baseline), day 30 and day 60 | |
Secondary | Fasting estimate of insulin resistance | HOMA-IR (Homeostasis model assessment estimated insulin resistance) will be calculated using the glucose and insulin data. | Day 0 (baseline), day 30 and day 60 | |
Secondary | Fasting estimate of insulin sensitivity | QUICKI (Quantitative Insulin Sensitivity Check Index) will be calculated using the glucose and insulin data. | Day 0 (baseline), day 30 and day 60 | |
Secondary | Postprandial glucose concentrations after consuming the faba bean-enriched bread and control bread. | Serum glucose will be measured in the postprandial blood samples collected for 360 minutes after each acute test meal. | Acute study on Days 0 and 30, blood taken prior to eating the test meal (0 minutes) and then at 15, 30, 45, 60, 90, 120, 180, 240, 300 and 360 minutes post meal ingestion | |
Secondary | Postprandial insulin concentrations after consuming the faba bean-enriched bread and control bread. | Serum insulin will be measured in the postprandial blood samples collected for 360 minutes after each acute test meal. | Acute study on Days 0 and 30, blood taken prior to eating the test meal (0 minutes) and then at 15, 30, 45, 60, 90, 120, 180, 240, 300 and 360 minutes post meal ingestion | |
Secondary | Fasting and postprandial concentrations of gut hormones | C-peptide, PYY, GIP and GLP-1 will be measured using a Luminex multiplex assay. | Acute study on Days 0 and 30, blood taken before meal ingestion at 0 minutes and then at 15, 30, 45, 60, 90, 120, 180, 240, 300 and 360 minutes post meal ingestion | |
Secondary | Fasting apolipoprotein B concentration | Serum apolipoprotein B will be measured using a clinical chemistry analyser. | Day 0 (baseline), day 30 and day 60 | |
Secondary | Postprandial apolipoprotein B concentrations after consuming the faba bean-enriched bread and control bread. | Serum apolipoprotein B concentrations will be measured using a clinical chemistry analyser. | Acute study on Days 0 and 30, blood taken prior to eating the test meal (0 minutes) and then at 60, 120, 180, 240, 300 and 360 minutes post meal ingestion. | |
Secondary | Fasting and postprandial concentrations of amino acids | Individual amino acids | Acute study on Days 0 and 30, blood taken before eating the test meal (0 minutes) and then at 15, 30, 45, 60, 90, 120, 180, 240, 300 and 360 minutes post meal ingestion | |
Secondary | Height | Height will be measured to the nearest cm using a stadiometer | Day 0 (baseline) | |
Secondary | Body weight | Body weight will be measured using a Tanita scale. | Day 0 (baseline), day 30 and day 60 | |
Secondary | Body fat percentage | Body fat percentage will be measured using a Tanita scale by bioelectrical impedance. | Day 0 (baseline), day 30 and day 60 | |
Secondary | Body fat mass and lean mass | Body fat mass and lean mass will be measured using a Tanita scale by bioelectrical impedance. | Day 0 (baseline), day 30 and day 60 | |
Secondary | Body mass index calculation | Body mass index will be calculated using the body weight (kg) and height data (m). | Day 0 (baseline), day 30 and day 60 | |
Secondary | Waist and hip circumferences | A non-stretch tape measure will be used to measure the waist and hip circumferences in cm. | Day 0 (baseline), day 30 and day 60 | |
Secondary | Clinic blood pressure | Systolic blood pressure, diastolic blood pressure and pulse pressure | Day 0 (baseline), day 30 and day 60 | |
Secondary | Postprandial feelings of satiety_7 hour study visit (long day) | 100 mm visual analogue scale. This scale is well validated for measuring appetite and satiety. Each rating score is out of 100. | Acute study on Days 0 and 30, prior to eating the test meal (0 minutes) and then at 15, 30, 60, 120, 240 and 360 minutes post meal ingestion | |
Secondary | Postprandial feelings of satiety_2 hour study visit (short day) | 100 mm visual analogue scale. This scale is well validated for measuring appetite and satiety. Each rating score is out of 100. | Days 1, 2, 31 and 32 prior to eating the test meal (0 minutes) and then at 15, 30, 60 and 120 minutes post meal ingestion. | |
Secondary | Habitual dietary intake of the study participants | Record of food and drink intake prior to each study visit. | Day 0 (baseline), day 30 and day 60 | |
Secondary | Fasting blood samples stored for future ethically approved research related to the project aims and objectives. | Spare whole blood and plasma/serum samples will be collected and biobanked for future research | Day 0 (baseline), day 30 and day 60 | |
Secondary | Postprandial blood samples stored for future ethically approved research related to the study aims and objectives. | Spare plasma/serum samples will be biobanked for future research | Acute study on Days 0 and 30, blood taken prior to eating the test meal (0 minutes) and then at 15, 30, 45, 60, 90, 120, 180, 240, 300 and 360 minutes post meal ingestion. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04435574 -
Lactoferrin for Treatment of Iron Deficiency Anemia.
|
Phase 4 | |
Not yet recruiting |
NCT05467319 -
Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS
|
Phase 3 | |
Not yet recruiting |
NCT05050851 -
Nutritional Parameters and Other Risk Factors Affecting Severity of Pneumonia in Children Under Five Years in Upper Egypt
|
||
Recruiting |
NCT04278651 -
Early Antenatal Support for Iron Deficiency Anemia
|
Phase 4 | |
Recruiting |
NCT04626414 -
Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT03800446 -
Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood
|
N/A | |
Recruiting |
NCT05304442 -
IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department
|
Phase 3 | |
Enrolling by invitation |
NCT03897673 -
Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas
|
N/A | |
Completed |
NCT05047211 -
Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia
|
Phase 4 | |
Not yet recruiting |
NCT06061393 -
Comparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia
|
Phase 4 | |
Completed |
NCT05190263 -
Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma
|
||
Completed |
NCT03318055 -
Prevalence of Hyperglycemia and Anaemia in Elective Surgical Patients
|
||
Completed |
NCT04631679 -
Investigation of the Wash-out Effect of Intravenous Iron by Cell Savers (WASH-OUT)
|
||
Recruiting |
NCT05225545 -
Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis
|
Phase 3 | |
Recruiting |
NCT03347513 -
Eradication of H-pylori in Pregnancy and Its Effect on Iron Replacement Therapy?
|
Phase 4 | |
Recruiting |
NCT04708665 -
Iron Deficiency Anemia and Non-iron Deficiency Anemia in Pregnancy in India
|
||
Completed |
NCT02404012 -
Iron Supplement to Improve Iron Status Following Bariatric Surgery
|
N/A | |
Completed |
NCT04137354 -
Iron and Vitamin A in School Children
|
N/A | |
Not yet recruiting |
NCT06096103 -
A Clinical Study to Check the Safety and Effectiveness of Botanical Extract Standardized for Iron + Vitamin c and Botanical Extract Standardized for Iron in Adult Human Subjects With Anemia or Iron-deficiency Anemia
|
N/A | |
Completed |
NCT03156712 -
Iron Absorption From Iron-enriched Aspergillus Oryzae
|
N/A |